Omega-3 (fish oil, krill oil, algal oil) trials recruiting now
40 registrations that name omega-3 as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 40 registrations
Status
Phase
16US sites across 9 states
1
2 to 4
5 to 19
20 or more
All 40 registrations
RecruitingNCT06055894
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
No phase
Memorial Sloan Kettering Cancer Center
About 200 people
Started Sep 20, 2023
In plain words A study of omega-3 in people 18 and older, run by Memorial Sloan Kettering Cancer Center. It plans to enroll about 200 people at 7 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Multiple Myeloma, Smoldering; Multiple Myeloma; Monoclonal Gammopathy of Undetermined Significance.
Confirmed prior diagnosis MGUS or of smoldering myeloma (any time prior). However, confirmation of diagnosis must be documented in their last local oncologist clinic note within 6 months prior to study enrollment.
Age ≥18 years
Willingness to comply with all study-related procedures
Physically able to complete requirements for the study or has someone to assist with the requirements (such as meal preparation, stool shipment and survey completion)
4 more inclusion criteria and the exclusion criteria are on the listing.
The researchers are going this to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks. All participants will have smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS). The researchers will compare how the different dietary changes affect butyrate levels in participants' stool.
Where, as registered
7 US sites in 2 states.
RecruitingNCT06195306
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
Phase 2
National Cancer Institute (NCI)
About 66 people
Started Jul 28, 2025
In plain words A Phase 2 study of omega-3 in female participants 45 to 74, run by National Cancer Institute (NCI). It plans to enroll about 66 people at 3 US sites.
Who it lists and where
Who the trial lists, as registered
Lists female participants 45 to 74; healthy volunteers accepted. Conditions: Breast Atypical Hyperplasia; Breast Carcinoma; Breast Ductal Carcinoma In Situ; Breast Lobular Carcinoma In Situ.
Age 45 - 74
Postmenopausal female
Postmenopausal is defined as either
Prior removal of the ovaries, or if ovaries intact amenorrhea for >= 12 months and not on any form of contraception, or
48 more inclusion criteria and the exclusion criteria are on the listing.
This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen is approved by the Food and Drug Administration for prevention of breast cancer in women at increased risk. Omega-3 fatty acids have been shown to decrease the amount of fats made in the liver. The full summary is on the listing.
Where, as registered
3 US sites in 3 states.
RecruitingNCT07078344
Omega-3D: Omega-3 for Diet-Driven Health Disparities
Phase 2
University of Arizona
About 200 people
Started Jul 31, 2025
In plain words A Phase 2 study of omega-3 in people 18 to 64, run by University of Arizona. It plans to enroll about 200 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 64; healthy volunteers accepted. Conditions: Heart Health Markers; Cardiovascular Diseases; Omega 3 Fatty Acids.
Age ≥ 18 years
BMI ≥ 18.5 kg/m2
Self-identify as non-Hispanic African American or non-Hispanic European American
Ability and willingness to transport for regular clinic visits.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Omega-3 Fatty Acids and Safflower Oil Placebo; Safflower Oil Placebo and Omega-3 Fatty Acids
Registered summary
The goal of this clinical trial is to learn whether omega-3 fatty acid supplementation can reduce inflammation-related biomarkers and improve cardiovascular health in healthy adult volunteers with different genetic backgrounds. The main questions it aims to answer are: Does the response to omega-3 supplementation differ based on genetic variation in the FADS gene cluster (specifically rs174537)? Are changes in fatty acid ratios and inflammation markers greater among individuals of African ancestry compared to those of European ancestry? Researchers will compare omega-3 supplements to a… The full summary is on the listing.
Where, as registered
2 US sites in 2 states.
RecruitingNCT06736925
Omega-3 Fatty Acids and Subconcussive Head Impacts
No phase
Indiana University
About 208 people
Started Feb 28, 2025
In plain words A study of omega-3 in people 18 to 30, run by Indiana University. It plans to enroll about 208 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 30; healthy volunteers accepted. Conditions: Subconcussive Head Impact; Omega-3 Fatty Acids.
Between age 18-30
Current or former soccer player
At least 5 years of soccer heading experience
Have internet access
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Omega-3 Fatty Acids (EPA plus DHA); Organic soybean oil; Soccer Heading Model
Registered summary
The purpose of the proposed double-blind, randomized placebo-controlled trial is to understand how supplementation with fish oil \[docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)\] promote brain health against soccer heading. The study involves taking DHA+EPA or placebo, questionnaires, blood draws, brain imaging, tests to evaluate heart function, and soccer headings.
Where, as registered
1 US site in 1 state.
RecruitingNCT06933095
Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia
No phase
University of Cincinnati
About 153 people
Started Sep 15, 2024
In plain words A study of omega-3 in people 55 to 82, run by University of Cincinnati. It plans to enroll about 153 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 55 to 82. Conditions: Eldery People; Cognitive Decline; Memory Decline; DHA CNS Delivery.
men and women 55 to 82 years old;
presence of subjective cognitive decline or mild cognitive decline using the SCD questionnaire, DEX, EMQ, MoCA; and mCDR;
No contraindication to a lumbar puncture (LP) unless opting to not have the LP (e.g., thrombocytopenia, coagulopathy, concomitant use of anticoagulant medications, etc.);
fluency in English;
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)
Registered summary
The purpose of this placebo-controlled trial is to compare the effects of 24-weeks supplementation with LPC-DHA and TAG-DHA on cerebrospinal fluid and blood DHA levels, as well as biomarkers of central neurodegenerative and neurotrophic activity, in elderly adults experiencing early signs of cognitive/memory decline including those with mild cognitive impairment (MCI). Extant evidence supports our overarching hypothesis that LPC-DHA supplementation will be more effective than TAG-DHA for increasing central (CSF) DHA levels and improving biomarker profiles in elderly adults. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06489873
Lutein, Zeaxathin, and Fish Oil Supplementation
No phase
Texas A&M University
About 80 people
Started Feb 7, 2024
In plain words A study of omega-3 in people 18 to 45, run by Texas A&M University. It plans to enroll about 80 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: Cognitive Performance; Age-Related Macular Degeneration; Bone Loss.
<.43 MPOD, a self-reported best-corrected vision of 20/40 or better in each eye, a BMI range of 18.5-30, and meets the inclusion criteria on the preliminary participant questionnaire.
The exclusion criteria are on the listing.
What it tests, as registered
Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF); Placebo Comparator
Registered summary
The goal of this clinical trial is to learn the impact of lutein, zeaxanthin, and fish oil (LZF) supplementation in healthy adults. The main question it aims to answer is: Will supplementation with LZF improve macular pigment optical density (MPOD), cognitive performance and bone mass compared to controls after six months? Subjects with an MPOD \<.43 will significantly improve MPOD after 6-months of LZF supplementation. Consuming a LZFO supplement for 6-months will improve visual cognitive performance. Consuming a LZFO supplement for 6-months will improve bone density. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05822141
Omega-3 Fatty Acids as Regulators of Brown Adipose Tissue During Cold Exposure
No phase
Indiana University
About 30 people
Started Jun 12, 2023
In plain words A study of omega-3 in people 18 to 40, run by Indiana University. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 40; healthy volunteers accepted. Conditions: Cold Exposure.
Male and female, between the ages of 18 to 40 years.
Body Mass Index (BMI) of 18.5 to 24.9 kg/m2
Considered "moderately to highly active" by the International Physical Activity Questionnaire (IPAQ) and the Physical Activity Readiness Questionnaire (PAR-Q+)
The exclusion criteria are on the listing.
What it tests, as registered
Fish Oil; Placebo
Registered summary
This clinical trial will assess the whether fish oil supplementation can modulate brown fat activation, shivering, thermal comfort and skin blood flow during cold exposure.
Where, as registered
1 US site in 1 state.
RecruitingNCT06279793
Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients
Phase 2
GCP-Service International West GmbH
About 550 people
Started Feb 15, 2024
In plain words A Phase 2 study of omega-3 in people 18 and older, run by GCP-Service International West GmbH. It plans to enroll about 550 people at 10 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Intensive Care Unit; Coronary Artery Bypass Grafting (CABG); High Risk Patients; Cardiopulmonary Bypass; Elective Cardiac Surgery; Valvular Heart Surgery; Multiple Valve Surgeries; Combined Cardiac Procedures; Aortic Surgical Procedures; Adult Patients ≥ 18 Years; Combined Valve and CABG; Combined Cardiac and Aortic Surgical Procedures.
Written informed consent prior to study participation
Adult patients (≥ 18 years)
Patients scheduled to undergo elective cardiac surgery with the use of CPB, who are defined as high risk based on having (i) one of the following surgical procedures: valvular heart surgery only, CABG, combined valve and CABG, multiple…
The exclusion criteria are on the listing.
What it tests, as registered
Fish Oil; Intravenous 0.9% Sodium Chloride
Registered summary
The MODIFY CSX study is a prospective, randomized, placebo-controlled trial conducted in heart centers in Germany and Italy. A total of 550 high-risk cardiac surgery patients will receive either 0.20 g fish oil/kg body weight (BW) + standard of care versus same volume of placebo (NaCl) + standard of care.
Where, as registered
No US site; Germany (10).
RecruitingNCT07314593
Omega-Cold Supplementation With Free Fatty Acids for the Prevention of Respiratory Infections in Adults.
No phase
Landspitali University Hospital
About 400 people
Started Dec 19, 2025
In plain words A study of omega-3 in people 18 to 80, run by Landspitali University Hospital. It plans to enroll about 400 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80; healthy volunteers accepted. Conditions: Respiratory Infections.
to be in general good health
18 to 80 years of age
willing and able to take fish oil orally.
The exclusion criteria are on the listing.
What it tests, as registered
Omega-3 oil with 2% Free Fatty Acids; Vegatable oil
Registered summary
The purpose of this study is to investigate whether fish oil containing free fatty acids affects people's susceptibility to viral infections such as colds, influenza, and COVID-19, as well as the course of these illnesses. Omega Cold is purified fish oil with 2% added free fatty acids, making it similar in that respect to less-purified fish oils. Participants aged 18-80 in generally good health will be recruited through Matís' consumer mailing list and social media advertisements. A total of 400 participants are planned: 100 in the winter of 2025-2026 and 300 in the winter of 2026-2027. The full summary is on the listing.
Where, as registered
No US site; Iceland (1).
RecruitingNCT07331103
RESOLving INflammation Through Diet for Health (RESOLVIN)
No phase
Mario Negri Institute for Pharmacological Research
About 324 people
Started Nov 26, 2025
In plain words A study of omega-3 in people 55 and older, run by Mario Negri Institute for Pharmacological Research. It plans to enroll about 324 people at 9 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 55 and older. Conditions: Cardiovascular (CV) Risk; Inflammation; Omega 3.
Participants are subjects >55 y old from both sexes (>=40% women) with moderate to high cardiovascular risk (ANNEX 1: SCORE2, SCORE2-OP and SCORE2-Diabetes assessment).
The exclusion criteria are on the listing.
What it tests, as registered
Fish Oil; Camelina oil; Vitamin E
Registered summary
Hyperlipidemia is the main driver of atherosclerotic cardiovascular disease (ASCVD), both through direct effects and as trigger of the chronic inflammation behind a cardiovascular health-to-disease transition. While lipid-lowering is an effective way to reduce the ASCVD risk, the residual risk remains high. In addition, a substantial proportion of ASCVD events occur in the absence of overt hyperlipidemia. Several lines of evidence ranging from experimental models to population studies and interventional clinical trials support chronic inflammation as the causal residual risk of CVD. The full summary is on the listing.
Where, as registered
No US site; Italy (9).
RecruitingNCT06531460
Nutritional Therapy Enriched With Omega-3 in Patients With Lung Resection
No phase
National Institute of Respiratory Diseases, Mexico
About 310 people
Started Jul 25, 2024
In plain words A study of omega-3 in people 18 and older, run by National Institute of Respiratory Diseases, Mexico. It plans to enroll about 310 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Lung Cancer; Surgery.
Lung cancer diagnosis
Elective surgery for lung resection schedule at least four days before surgery
Signed informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
Fish oil enteral supplementation; Fish oil oral supplementation; Enteral nutrition without fish oil; Oral nutritional supplement without fish oil
Registered summary
The aim of this study is to analyze the effect of enriched formula with omega-3 in the 30-day incidence infection and inflammatory response following lung resection surgery in lung cancer patients.
Where, as registered
No US site; Mexico (1).
RecruitingNCT07643558
Effects of Dietary Supplementation With omega3-fatty Acids (Fish Oil) and Progressive Resistance Training on Skeletal Muscle Status in Gynaecological, Gastrointestinal and Urological Cancer Patients
No phase
University of Erlangen-Nürnberg Medical School
About 288 people
Started Jan 1, 2026
In plain words A study of omega-3 in people 18 and older, run by University of Erlangen-Nürnberg Medical School. It plans to enroll about 288 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Cancer Cachexia; Omega 3; Resistance Training; Cancer; Muscle Wasting; Systemic Inflammation.
Patients with malignant tumors undergoing curative or palliative treatment, including breast, ovarian, esophageal, pancreatic, gastric, colon, rectal, and prostate cancer, across all UICC stages
Women and men aged 18 years or older
ECOG performance status 0-2
The exclusion criteria are on the listing.
What it tests, as registered
Omega 3 FA (Fish Oil); Training; Corn Oil Placebo, 4 capsules/day for 12 weeks
Registered summary
Cancer cachexia is a common and prognostically relevant complication of advanced malignancies, characterized by systemic inflammation, increased catabolism, and reduced nutritional intake, leading to a progressive loss of skeletal muscle mass, physical performance, and quality of life. Muscle wasting negatively affects the tolerability and efficacy of oncological therapies and exacerbates distressing symptoms such as fatigue. Consequently, international guidelines recommend combined nutritional and exercise interventions as key components of supportive cancer care. The full summary is on the listing.
Where, as registered
No US site; Germany (1).
RecruitingNCT06928701
Impact of "Targeted" Nutritional Apport and Exercise on the Modulation of Metabolic and Immune-related Gene Expression Signatures in Early Breast Cancer (eBC) Patients Candidate to Neoadjuvant Therapy (NAT)
No phase
University of Eastern Piedmont
About 160 people
Started Sep 1, 2024
In plain words A study of omega-3 in female participants 18 and older, run by University of Eastern Piedmont. It plans to enroll about 160 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Early Breast Cancer; Neoadjuvant Treatment.
- Women (regardless of menopausal status) ≥ 18 years of age
Pathologic confirmation of breast cancer by tumor biopsy
Immunohistochemical assessment (as per local standards) of ER and PgR status, HER2 status;
Stage I-III breast cancer without evidence of distant metastases
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
omega-3 (n-3 Lc-PUFA), EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) plus a source of palmitoleic acid (hexadecenoic acid)
Registered summary
NEOMET is an exploratory randomized prospective, multicenter study whose primary aim is to explore if metabolomic signatures can be modified by a lifestyle intervention including dietary supplements and physical exercise intervention, in eBC patients candidate to NAT. Eligible patients will be randomised to one of 4 groups: A. NAT, according to molecular subtype; B. NAT plus nutritional supplementation; C. NAT plus supervised physical exercise; D. NAT plus supervised physical exercise plus nutritional supplementation. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
RecruitingNCT06424860
Fish Oil, Metformin and Heart Health in PCOS
Phase 1
University of Alberta
About 146 people
Started Nov 1, 2025
In plain words A Phase 1 study of omega-3 in female participants 25 to 45, run by University of Alberta. It plans to enroll about 146 people at 3 sites, none in the US.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Fish oil; Metformin; Fish Oil and Metformin
Registered summary
Women with Polycystic Ovary Syndrome (PCOS) have high testosterone levels which is associated with altered insulin-glucose metabolism and an adverse blood lipid profile, predisposing them to the development of Type II Diabetes and Cardiovascular Disease (CVD). This study will investigate the use of dietary fish oil supplementation as a safe and effective intervention, and as an adjunct therapy to standard of care treatment with metformin to improve heart health, blood lipids and insulin-glucose metabolism in women with PCOS, and those with PCOS and Type 2 Diabetes.
Where, as registered
No US site; Canada (3).
RecruitingNCT07272382
Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer
No phase
Fudan University
About 142 people
Started Jun 5, 2025
In plain words A study of omega-3 in people 18 and older, run by Fudan University. It plans to enroll about 142 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Esophageal Neoplasms.
This is a randomized, double-blind, placebo-controlled phase II clinical trial designed to evaluate whether adding omega-3 fatty acids improves outcomes in adult patients with recurrent or metastatic esophageal cancer receiving PD-1 inhibitor therapy. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT05404230
Prevention of Oxaliplatin-induced Nerve Damage in the Body's Extremities
No phase
Vejle Hospital
About 120 people
Started Jul 15, 2022
In plain words A study of omega-3 in people 18 and older, run by Vejle Hospital. It plans to enroll about 120 people at 4 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Peripheral Neuropathy; Colorectal Cancer.
Histopathologically verified adenocarcinoma of the colon or rectum and planned standard adjuvant treatment with capecitabine in combination with oxaliplatin.
ECOG performance status 0-2 (measurement of a patient's function in terms of self-care, daily activity and physical ability.
Written and orally informed informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Fish oil; Corn oil
Registered summary
The purpose of this study is to examine the effect of supplementary polyunsaturated fatty acids on nerve damage in the body's extremitites of patients treated with oxaliplatin containing chemotherapy after surgery for colorectal cancer.
Where, as registered
No US site; Denmark (4).
RecruitingNCT05589064
Evaluation of the Impact of a Dietary and Nutritional Intervention on Persistent Post-concussive Symptoms
No phase
Universite de Moncton
About 120 people
Started Oct 1, 2022
In plain words A study of omega-3 in people 16 and older, run by Universite de Moncton. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 16 and older. Conditions: Brain Injury Traumatic Mild.
16 years or older
Must be able to understand English or French
Have persistent post-concussive symptoms lasting at least 2 weeks but no longer than 6 months
The exclusion criteria are on the listing.
What it tests, as registered
Experimental: Dietetic counseling; Active Comparator: Omega-3, vitamin D3 and creatine monohydrate; Other : Physiotherapy treatment
Registered summary
Concussions affect thousands of Canadians every year. Although the effects are usually temporary, 10-15% of adults experience persistent symptoms likely to last several weeks or even months. It is suggested that nutritional interventions should be considered in concussion management because nutrition can act on several mechanisms of brain injury. However, to date, no study has assessed the impact of dietary interventions on the recovery of people with persistent post-concussive symptoms. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT06629103
A Study in Healthy Subjects to Compare the Bioavailability of EPA + DHA
Phase 4
RDC Clinical Pty Ltd
About 120 people
Started Aug 6, 2025
In plain words A Phase 4 study of omega-3 in people 18 to 64, run by RDC Clinical Pty Ltd. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 64; healthy volunteers accepted. Conditions: Optimal Absorption of Omega-3; Healthy.
Written informed consent obtained before any trial related assessments are performed.
2\. Healthy adult females ages 18-64 who are neither pregnant nor breastfeeding or healthy adult males ages 18-64 at the time of consent. a.
Participant's body mass index (BMI) must be between 18 and 30 kg/m2 (inclusive) and considered to be of healthy weight in the opinion of the investigator.
Intakes of EPA+DHA of less than 300mg per day based on the FFQ
The exclusion criteria are on the listing.
What it tests, as registered
life's Omega 1035DS; Fish Oil; Placebo; life's Omega O3020DS
Registered summary
This is a randomised, double-blind, parallel, placebo-controlled study in healthy subjects to compare the absorption of two microalgal formulations, to a fish oil and a placebo.
Where, as registered
No US site; Australia (1).
RecruitingNCT07462013
Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice
No phase
National Science and Technology Council, Taiwan
About 120 people
Started Oct 1, 2025
In plain words A study of omega-3 in people 50 to 80, run by National Science and Technology Council, Taiwan. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 80. Conditions: Major Depressive Disorder (MDD).
POWER project is a randomized, controlled, non-profit study with the primary objective of testing the effectiveness of non-pharmacological interventions-such as physical activity, cognitive training, and dietary supplementation-in reducing depressive symptoms and preventing or delaying cognitive impairments that frequently co-occur in individuals with Major Depressive Disorder (MDD).
Where, as registered
No US site; Taiwan (1).
RecruitingNCT04209244
Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia
No phase
Copenhagen University Hospital, Rigshospitalet
About 100 people
Started Dec 16, 2019
In plain words A study of omega-3 in people 1 to 45, run by Copenhagen University Hospital, Rigshospitalet. It plans to enroll about 100 people at 4 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 1 to 45. Conditions: Leukemia, Acute Lymphoblastic.
Children (1-17.9 years) and young adults (18-45 years) diagnosed with ALL, stratified to very-low risk (VRL), intermediate risk low (IR-low) and intermediate risk high (IR-high) in the ALLTogether protocol.
The exclusion criteria are on the listing.
What it tests, as registered
Eskimo-3 Pure Fish Oil; Rapeseed Oil
Registered summary
Acute lymphoblastic leukemia (ALL) is the most common malignant disease among children. Treatment results have improved over time due to intensive risk-adapted therapy and the 5-year survival rate is now above 90%. However, the burden of therapy has increased proportionally. Many children develop serious acute and chronic side effects, which impact on the patients expected lifespan and impair their quality of life as a result of therapy. Treatment with PEG-asparaginase and dexamethasone increases the levels of triglycerides and total cholesterol. The full summary is on the listing.
Where, as registered
No US site; Denmark (4).
RecruitingNCT05899660
Impact of Omega 3 in Alcohol Use Disorder
No phase
Université Catholique de Louvain
About 100 people
Started Jun 19, 2023
In plain words A study of omega-3 in people 18 to 70, run by Université Catholique de Louvain. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Alcohol Use Disorder, Severe.
Diagnosis of alcohol use disorder (≥ 4 DSM-5 criteria)
Patient at the hospital for a 3 week alcohol withdrawal program
Gender : male and female
Age : between 18 and 70 years old
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Active Comparator: Omega-3; Placebo Comparator: olive oil
Registered summary
The goal of this clinical trial is to investigate the biological pathways underlying the beneficial effect of omega-3 polyunsaturated fatty acids (n-3 PUFA) on mental health in patients with alcohol use disorder. The main questions this study aims to answer are: * Can n-3 PUFA improve mood disorders (depression, anxiety), craving for alcohol, cognitive impairments and sociability disorders ? * Are the beneficial effects of n-3 PUFAs due to a modification of the gut microbiota and/or the inflammatory status? Participants will : * take a supplementation of omega-3 or placebo during 3 months *… The full summary is on the listing.
Where, as registered
No US site; Belgium (1).
RecruitingNCT06074250
Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
Phase 2 and 3
The Canadian College of Naturopathic Medicine
About 100 people
Started Aug 15, 2024
In plain words A Phase 2 and 3 study of omega-3 in female participants 18 to 43, run by The Canadian College of Naturopathic Medicine. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 43. Conditions: Perinatal Depression; PerinatalAnxiety.
Women 18-43 years old
12-35 weeks of gestation
Non-smoker/alcohol/recreational drug user
Financially stable
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Fish oil; Probiotics; Prebiotics; Diet Quality
Registered summary
Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies. The adverse outcomes extend beyond maternal well-being to long-term deficits in children and families. The gut-brain axis is a newly recognized key player in mental health disorders. Specifically, the microbial composition of the gut along with their metabolites are directly involved in disease onset and course. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT07364331
Omega-3 Fatty Acids, Neuroendocrine and Attention Deficit Hyperactivity Disorder (OMNeADHD)
No phase
China Medical University Hospital
About 100 people
Started Sep 4, 2021
In plain words A study of omega-3 in people 6 to 18, run by China Medical University Hospital. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 6 to 18. Conditions: ADHD; Children; Adolescents.
DSM-5 diagnosis of ADHD
Did not have any changes of ADHD treatment (pharmacological/psychological) within 4 weeks of entering the trial.
SNAP-IV inattention subscale >=12, or hyperactivity subscale >=12, or inattention+ hyperactivity subscales >=24
The exclusion criteria are on the listing.
What it tests, as registered
Omega-3; Placebo
Registered summary
This is a 12 week randomized controlled study on the effects of omega-3 fatty acids in youth with attention deficit hyperactivity disorder (ADHD) with omega-3 deficiency.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT07575438
Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk Adults
Phase 2
May Faraj, PDt, PhD
About 84 people
Started Oct 5, 2026
In plain words A Phase 2 study of omega-3 in people 40 to 70, run by May Faraj, PDt, PhD. It plans to enroll about 84 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 70; healthy volunteers accepted. Conditions: Type 2 Diabetes; Prediabetes (Insulin Resistance, Impaired Glucose Tolerance); Prediabetes / Type 2 Diabetes; Obesity & Overweight; Obesity and Diabetes Mellitus, Type 2.
With a body mass index (BMI >25-40 kg/m2)
Having confirmed menopausal status (FSH ≥ 30 U/l)
Non-smokers (tobacco) or have quitted for over a year
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Fish Oil; Fish Oil; Corn oil control
Registered summary
The purpose of this clinical trial is to find out whether one type of fish oil works better than another at improving metabolic health in people who are at high risk of developing type 2 diabetes. Some metabolic problems-such as difficulty controlling blood sugar, unhealthy particles that transport cholesterol in the blood, and poor fat tissue function-can increase the risk of type 2 diabetes. This study aims to determine whether different types of fish oil can: 1. Improve how well the body produces insulin and responds to it, 2. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT06296875
The Krill Ageing Muscle Mechanisms (KAMM) Study
No phase
University of Glasgow
About 80 people
Started Sep 1, 2024
In plain words A study of omega-3 in people 65 to 90, run by University of Glasgow. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 65 to 90; healthy volunteers accepted. Conditions: Sarcopenia.
body mass index (BMI) </= 30 kg/m2
Age >/= 65 years
Capacity to consent
Living within the Glasgow area
The exclusion criteria are on the listing.
What it tests, as registered
Vegetable oil; Krill oil
Registered summary
This study aims to determine the mechanisms via which krill oil supplementation increases muscle strength and whether this translates to improvements in gait and functional characteristics in older adults. The studies we will carry out will establish, in healthy older adults, the effects of 6 months of supplementation with krill oil Objective 1) Muscle structure and function Hypothesis: Krill oil supplementation will increase muscle size and strength alongside positive changes in muscle architecture (pennation angle and fascicle length). The full summary is on the listing.
Where, as registered
No US site; United Kingdom (1).
RecruitingNCT06833554
The Role of Breast Milk Neutrophils From Mothers With Metabolic Diseases After Nutritional Intervention. Impact on Infant Development and Response to Pulmonary Infections
No phase
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
About 80 people
Started Jan 1, 2023
In plain words A study of omega-3 in female participants 18 to 50, run by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud. It plans to enroll about 80 people at 1 site, none in the US.
intention to practice exclusive breastfeeding for at least 3 months
The exclusion criteria are on the listing.
What it tests, as registered
Omega-3 Fatty Acids (EPA plus DHA); Placebo
Registered summary
This project aims at identifying variations in breast milk neutrophils among lactating mothers with gestational diabetes or obesity (objective 1), and to describe how a dietary intervention with Omega-3 fatty acids affects these changes (objective 2). The occurrence of respiratory infections on the progeny will be analysed, as well as its development and the impact on gut microbiota and epigenetic changes (objective 3). The involvement of breast milk on the neonate's microbiota (sub-objective 1) and epigenetic variations (sub-objective 2) will be depicted. The full summary is on the listing.
Where, as registered
No US site; Spain (1).
RecruitingNCT07665658
Effectiveness of Neuroplasticity-Targeted Supplements on Neuroinflammatory Markers, ADHD Symptom Severity, and Clinical Scores in Children
No phase
Khyber Medical University Peshawar
About 68 people
Started Mar 1, 2026
In plain words A study of omega-3 in people 6 to 12, run by Khyber Medical University Peshawar. It plans to enroll about 68 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 6 to 12. Conditions: Attention Deficit Hyperactivity Disorder.
DSM-5 confirmed ADHD diagnosis
Age 6-12 years
Medication-free or on stable stimulant medication (≥1 month)
This randomized controlled trial will evaluate the effectiveness of neuroplasticity-targeted supplements on neuroinflammatory markers and ADHD symptoms in children aged 6 to 12 years diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Participants will be randomly assigned to one of four groups: gut-targeted supplements (prebiotics and probiotics), brain-targeted supplements (omega-3 fatty acids and vitamin B1), combined supplementation, or placebo. The intervention period will last 12 weeks. The full summary is on the listing.
Where, as registered
No US site; Pakistan (1).
RecruitingNCT07363551
Omega-3 Fatty Acids, Inflammation, Gut Microbiota in Youth With Depression
No phase
China Medical University Hospital
About 60 people
Started Jun 9, 2021
In plain words A study of omega-3 in people 13 to 18, run by China Medical University Hospital. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 13 to 18. Conditions: ADHD.
Youth with a DSM-5 diagnosis of MDE
The exclusion criteria are on the listing.
What it tests, as registered
Omega-3 fatty acids; Placebo
Registered summary
This is a 12 week double blind RCT aimed to investigate the role of omega-3 fatty acids in patients with major depressive disorder
Where, as registered
No US site; Taiwan (1).
RecruitingNCT07365553
Omega-3, Autism Spectrum Disorder (ASD)
No phase
China Medical University Hospital
About 50 people
Started Jul 15, 2022
In plain words A study of omega-3 in people 6 to 17, run by China Medical University Hospital. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 6 to 17. Conditions: ASD.
diagnosis of DSM5 ASD made by child and adolescent psychiatrist
age 6-17 years-old at the time of enrolment
no pharmacotherapy or non-pharmacotherapy adjustment within the past 4 weeks,
Signed informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
Omega-3; Placebo
Registered summary
This is a 12 week study to investigate the effects of omega-3 polyunsaturated fatty acids (PUFAs) in youth with autism spectrum disorder (ASD).
Where, as registered
No US site; Taiwan (1).
RecruitingNCT07439744
NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status
No phase
National Science and Technology Council, Taiwan
About 50 people
Started Mar 1, 2025
In plain words A study of omega-3 in people 18 to 54, run by National Science and Technology Council, Taiwan. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 54. Conditions: Obese Adults; MDD.
A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \< 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT04485871
Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids
No phase
Institut de Recherches Cliniques de Montreal
About 48 people
Started Dec 19, 2019
In plain words A study of omega-3 in people 45 to 74, run by Institut de Recherches Cliniques de Montreal. It plans to enroll about 48 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 45 to 74; healthy volunteers accepted. Conditions: Type 2 Diabetes; Inflammation; Insulin Sensitivity/Resistance; Fatty Acids, Omega-3.
Having a body mass index (BMI= 25-40 kg/m2)
Aged between 45 and 74 years
Having confirmed menopausal status (FSH ≥ 30 U/l)
Non-smoker
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Omega-3 fatty acids
Registered summary
Every 3 minutes a new case of diabetes is diagnosed in Canada, mostly type 2 diabetes (T2D) increasing the risk for heart disease. T2D and heart disease share many common risk factors such as aging, obesity and unhealthy lifestyle. Paradoxically however, while lowering blood LDL, commonly known as "bad cholesterol", is protective against heart disease, research over the past 10 years have shown that the lower is blood LDL, the higher is the chance of developing T2D. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT06695910
Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA).
Phase 4
Samuel Fortin
About 48 people
Started Nov 6, 2024
In plain words A Phase 4 study of omega-3 in people 19 to 55, run by Samuel Fortin. It plans to enroll about 48 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 19 to 55; healthy volunteers accepted. Conditions: Brain Fog; Cognitive Health.
Participant between 19 and 55 years of age.
Participant who reports having mental fatigue and/or frequent memory loss and/or difficulty concentrating and/or inattention, confusion and/or a feeling of decreased cognitive acuity for at least 28 days at the time of selection.
Participant who obtains a mean score on the BFS screening questionnaires (BFS1 and BFS2) total of at least 30 and/OR who obtains the following minimum score on at least one of the three factors: Factor 1 of at least 15 and/or Factor 2 of…
Available for the entire duration of the study and willing to participate based on the information provided in the ICF duly read and signed by the latter.
2 more inclusion criteria and the exclusion criteria are on the listing.
A growing body of studies shows that omega-3s act directly in molecular signaling pathways that reduce inflammation and are thought to have a positive effect on cognitive health. Brain fog is a term that has been popularized in the medical world in the wake of the COVID-19 pandemic. A significant proportion of patients with long COVID reported having cognitive sequelae that were like fogginess. The full summary is on the listing.
Where, as registered
No US site; Canada (2).
RecruitingNCT06015971
Omega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer
No phase
Maimónides Biomedical Research Institute of Córdoba
About 40 people
Started Jul 1, 2023
In plain words A study of omega-3 in people 18 and older, run by Maimónides Biomedical Research Institute of Córdoba. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Sarcopenia.
- Patients with Gastrointestinal tumor undergoing systemic treatment (chemo-radio-immuno therapy or their combination)
Body weight loss >5% in the previous three months or >10% in the previous six months
Both sexes
Age between 18-85 y-old.
The exclusion criteria are on the listing.
What it tests, as registered
omega-3; Standard
Registered summary
Sarcopenia is a frequent complication in patients with cancer and chronic diseases, it is characterized by decreased muscle strength and fatigue due to reduced skeletal muscle mass, which is accompanied by atrophy and decreased quality of muscle tissue. In all cases, it negatively impacts treatment tolerance, clinical outcomes and survival, in consequence, quality of life of these patients decreases while morbidity, mortality and costs increase. The full summary is on the listing.
Where, as registered
No US site; Spain (1).
RecruitingNCT07118059
Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial
Phase 2
North-West University, South Africa
About 40 people
Started Aug 19, 2026
In plain words A Phase 2 study of omega-3 in people 18 to 45, run by North-West University, South Africa. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45. Conditions: Tuberculosis; Inflammation Biomarkers; Liver Function Tests; Iron Status; Metabolomics; Nutritional Status; Clinical Outcomes.
adults aged 18-45 years
laboratory confirmed Pulmonary TB defined as a hard copy of a sputum result detected by WHO recommended assay or mycobacteria culture.
Women of childbearing potential with a negative pregnancy test on enrollment
All participant irrespective of HIV status who consent to have a HIV test during enrollment.
The exclusion criteria are on the listing.
What it tests, as registered
Omega-3 (EPA+DHA); Placebo
Registered summary
The goal of this randomized controlled trial is to evaluate the early bactericidal activity, early inflammatory response, and safety of omega-3 long chain polyunsaturated fatty acid (n-3 PUFA) supplementation in adult patients (aged 18- 45 years) with newly diagnosed, bacteriologically confirmed drug-sensitive pulmonary tuberculosis. The full summary is on the listing.
Where, as registered
No US site; South Africa (1).
RecruitingNCT07673185
Omega-3 Plus Low-Dose Aspirin in Smokers With Stage III Periodontitis
No phase
Al-Azhar University
About 40 people
Started Jan 15, 2025
In plain words A study of omega-3 in people 30 to 50, run by Al-Azhar University. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 30 to 50. Conditions: Periodontal Disease; Periodontitis (Stage 3); Smoking Behaviors.
- Male or female smokers aged 30 to 50 years.
Diagnosed with Stage III periodontitis according to the 2017 World Workshop classification.
Probing pocket depth (PPD) ≥ 5 mm.
Clinical attachment loss (CAL) ≥ 5 mm.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Omega-3 Fatty Acids (EPA plus DHA) plus low dose aspirin; Placebo
Registered summary
This randomized double-blind placebo-controlled clinical trial aims to evaluate the clinical and biochemical effects of omega-3 fatty acids combined with low-dose aspirin as an adjunct to scaling and root planing (SRP) in smoker patients with Stage III periodontitis. The study compares test and control groups regarding periodontal clinical parameters and gingival crevicular fluid interleukin-1 beta (IL-1β) levels Or other inflammatory markers that will be determined later at baseline, 3 months, and 6 months following treatment
Where, as registered
No US site; Egypt (1).
RecruitingNCT07740967
Dietary Supplements and Middle Aged Women (Collagen & Omega)
No phase
Loughborough University
About 34 people
Started May 1, 2026
In plain words A study of omega-3 in female participants 35 to 65, run by Loughborough University. It plans to enroll about 34 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 35 to 65; healthy volunteers accepted. Conditions: Cognition; Inflammation Biomarkers; Bone Metabolism Biomarkers; Fatigue Symptom; Sleep; Body Composition Changes; Joint Pain; Quality of Life; Gastrointestinal Comfort; Blood Pressure and Augmentation Index; Muscle Strength; Fatty Acid Blood Profile.
Female
Age 35 - 65 years old
Healthy, free from known disease
Non-smoker
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Collagen peptides and omega-3; Placebo control
Registered summary
This study will examine the effects of combining different types of dietary supplements on various aspects of health and wellbeing in middle aged women. The main outcomes of the trial will be aspects of health and wellbeing that middle aged women report as increasingly problematic, such as joint pain, fatigue, sleep, and changes in body composition, strength, and inflammation. Participants will consume the supplement(s) or placebo for 8 weeks, and outcome measures will be assessed before and after supplementation.
Where, as registered
No US site; United Kingdom (1).
RecruitingNCT06939244
Investigating the Effects of Krill Oil on the Recovery From Muscle Damaging Exercise: a Randomised Controlled Trial
No phase
University of Glasgow
About 32 people
Started Feb 1, 2025
In plain words A study of omega-3 in people 60 and older, run by University of Glasgow. It plans to enroll about 32 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 60 and older; healthy volunteers accepted. Conditions: Looking at the Effects of Krill Oil Supplementation on Recovery From Muscle-damaging Exercise.
Be 60 years old or older
Have a BMI of less than 30kg/m2
Participating in resistance-type exercise for less than 1h per week
The exclusion criteria are on the listing.
What it tests, as registered
Krill oil
Registered summary
1\. What will happen to me if I take part? All study visits will be at the University of Glasgow main campus within the Sir James Black building. Initial visit (duration 1 hours) We will ask that for each study visit you come to the laboratory with clothing suitable to exercise in (loose shorts) for your own comfort and to also make it easier for us to complete certain measurements where access to upper legs will be necessary. Changing facilitates will be provided on-site. After the screening process, your physical activity and your diet will be assessed via questionnaires. The full summary is on the listing.
Where, as registered
No US site; United Kingdom (1).
RecruitingNCT07130513
Investigating the Feasibility of Krill Oil Intervention to Improve Muscle Function in Adults With Long-term Conditions
No phase
University of Glasgow
About 30 people
Started Aug 18, 2025
In plain words A study of omega-3 in people 18 and older, run by University of Glasgow. It plans to enroll about 30 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Krill Oil; Muscle Function; Grip Strength; Long-Term Conditions; Omega 3 Fatty Acids.
Men and women aged ≥18 years who are in the high-risk long-term condition group (having one or more LTCs, including rheumatoid arthritis, gout, type 2 diabetes, coronary heart disease, and stroke \[including transient ischemic attack,…
The exclusion criteria are on the listing.
What it tests, as registered
Krill oil supplementation; Control
Registered summary
This study will recruit 30 adults (men and women, aged 18 years and over) who will be randomly assigned to one of two groups in a 12-week double-blind pilot trial. Participants will receive either: * Arm 1: Krill Oil group: 4 g/day of krill oil supplements (Superba™ Antarctic Krill Oil, 1000 mg capsules), or * Arm 2: Control group: 4 g/day of placebo (vegetable oil capsules). Participants will be instructed to maintain their usual diet and physical activity patterns throughout the study. The full summary is on the listing.
Where, as registered
No US site; United Kingdom (2).
RecruitingNCT07586839
Effect of a Nutritional Supplement on Muscle Recovery
No phase
Wageningen University
About 28 people
Started Sep 26, 2025
In plain words A study of omega-3 in male participants 18 to 35, run by Wageningen University. It plans to enroll about 28 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 to 35; healthy volunteers accepted. Conditions: Healthy.
Young (≥18 and ≤35 years)
Male sex
Non-obese (≥18.5 and ≤27.5 kg/m2)
Recreationally active (performing non-competitive exercise at least one time a week for minimally 30 minutes)
The exclusion criteria are on the listing.
What it tests, as registered
Control drink; Vegan supplement containing caprylic acid and omega-3 fatty acids
Registered summary
The aim is to develop a food supplement drink that supports muscle health by combining specific fatty acids, which can positively affect metabolic and inflammation processes that are important for muscle health.
Where, as registered
No US site; Netherlands (1).
RecruitingNCT05465252
Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression
No phase
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
About 24 people
Started Oct 17, 2025
In plain words A study of omega-3 in people 50 to 85, run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. It plans to enroll about 24 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 85. Conditions: Age-Related Macular Degeneration.
Adults diagnosed with dry AMD at an early or intermediate stage, classified according to the Beckman Classification and confirmed by fundus photography: (1) Early AMD: medium drusen (>63 μm and ≤125 μm) without AMD-related pigmentary…
Willing to stop supplementation of omega-3 fatty acids, choline, or astaxanthin.
Willing to sign the informed consent, and willing to attend follow-up visits for at least 3 months.
The exclusion criteria are on the listing.
What it tests, as registered
Krill Oil; Olive Oil
Registered summary
This randomized, double-blind, placebo-controlled study aims to evaluate the effect of krill oil supplementation in patients with dry age-related macular degeneration (AMD). Participants will receive 4 capsules of krill oil or placebo daily for a period of 3 months. Outcomes will be evaluated after 3-month treatment to assess differences between the two study groups.